Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Source: GlobeNewswire· Sanofi Winthrop Industrie· August 4, 2026
SynaBot summary
The European Commission has approved Sanofi's MenQuadfi vaccine for infants as young as six weeks old. This marks a significant expansion of its availability, offering protection against invasive meningococcal disease earlier in life.
Key takeaways
- EU greenlights MenQuadfi for infants from six weeks old.
- Vaccine targets invasive meningococcal disease.
- Earlier protection now available for young children.
- Expands options for pediatric vaccination programs.
Why it matters
This development means healthcare professionals and parents now have an earlier option for protecting infants from a serious disease. For those managing health-related AI tools, this expands the data and considerations for early childhood vaccination protocols.
This story was reported by GlobeNewswire. Read the full original article:
Read on GlobeNewswire Try this on SynaBot
Related AI assistants, prompts, and tools from the SynaBot catalog.
AI Assistants
AI Tools
- WritereleaseWriterelease is an AI tool designed for teams to streamline the press release creation process, supporting various AI-assisted workflows for both business and personal use cases.
- BotpressBotpress is an open-source platform for creating powerful conversational AI assistants. It offers flexibility for developers to build custom chatbots with extensive integrations and natural language understanding.
